ROSELAND, NJ / ACCESSWIRE /
June 29, 2020 / Milestone Scientific Inc. (NYSE
American:MLSS), a
leading developer of computerized drug delivery
instruments that provide painless and precise
injections, today announced that it has been added to
the Russell 3000® and
Russell Microcap® Indexes,
following the annual Russell indexes reconstitution,
effective after the market open on June 29, according to
a final list of additions posted on June 26.
Annual Russell indexes reconstitution captures the 4,000
largest US stocks as of May 8, ranking them by total
market capitalization. Membership in the US all-cap
Russell 3000® Index,
which remains in place for one year, means automatic
inclusion in the large-cap Russell 1000® Index
or small-cap Russell 2000® Index
as well as the appropriate growth and value style
indexes. Membership in the Russell Microcap® Index,
which remains in place for one year, means automatic
inclusion in the appropriate growth and value style
indexes. FTSE Russell determines membership for its
Russell indexes primarily by objective,
market-capitalization rankings and style attributes.
Leonard Osser, CEO of Milestone Scientific, stated,
"We're pleased to be included in the Russell 3000® and
Russell Microcap® Indexes.
These additions reflect our continued progress as we
move forward with the launch of our medical instruments
based on our proprietary Dynamic Pressure Sensing
technology®.
We believe our inclusion in the Russell Indexes will
help improve awareness, liquidity and exposure within
the global community of institutional investors."
Russell indexes are widely used by investment managers
and institutional investors for index funds and as
benchmarks for active investment strategies.
Approximately $9 trillion in assets are benchmarked
against Russell's US indexes. Russell indexes are part
of FTSE Russell, a leading global index provider. For
more information on the Russell 3000® Index,
Russell Microcap® Index
and the Russell indexes reconstitution, go to the
"Russell Reconstitution" section on the FTSE
Russell website.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a biomedical
technology research and development company that
patents, designs and develops innovative diagnostic and
therapeutic injection technologies and instruments for
medical, dental, cosmetic and veterinary applications.
Milestone's computer-controlled systems are designed to
make injections precise, efficient, and virtually
painless. Milestone's proprietary DPS Dynamic Pressure
Sensing technology® is our technology platform that
advances the development of next-generation devices,
regulating flow rate and monitoring pressure from the
tip of the needle, through platform extensions for local
anesthesia for subcutaneous drug delivery, with specific
applications for cosmetic botulinum toxin injections,
epidural space identification in regional anesthesia
procedures and intra-articular joint injections. For
more information please visit our website: www.milestonescientific.com.
About FTSE Russell
FTSE Russell is a leading global index provider creating
and managing a wide range of indexes, data and analytic
solutions to meet client needs across asset classes,
style and strategies. Covering 98% of the investable
market, FTSE Russell indexes offer a true picture of
global markets, combined with the specialist knowledge
gained from developing local benchmarks around the
world.
FTSE Russell index expertise and products are used
extensively by institutional and retail investors
globally. Approximately $16 trillion is currently
benchmarked to FTSE Russell indexes. For over 30 years,
leading asset owners, asset managers, ETF providers and
investment banks have chosen FTSE Russell indexes to
benchmark their investment performance and create
investment funds, ETFs, structured products and
index-based derivatives. FTSE Russell indexes also
provide clients with tools for asset allocation,
investment strategy analysis and risk management.
A
core set of universal principles guides FTSE Russell
index design and management: a transparent rules-based
methodology is informed by independent committees of
leading market participants. FTSE Russell is focused on
index innovation and customer partnership applying the
highest industry standards and embracing the IOSCO
Principles. FTSE Russell is wholly owned by London Stock
Exchange Group.
For
more information, visit www.ftserussell.com.
MORE NEWS
Mon Jun 29th, 2020
-
ACCESSWIRE8:00
AMMilestone
Scientific Added to Russell 3000(R) and Russell
Microcap(R) Indexes
ROSELAND, NJ / ACCESSWIRE / June 29, 2020 /
Milestone Scientific Inc. (NYSE American:MLSS) ,
a leading developer of computerized drug
delivery instruments that provide painless and
precise injections, today announced that it has
been added to the Russell 3000 ® and Russell
Microcap...
Safe Harbor Statement
This press release
contains forward-looking statements regarding the timing
and financial impact of Milestone's ability to implement
its business plan, expected revenues, timing of
regulatory approvals and future success. These
statements involve a number of risks and uncertainties
and are based on assumptions involving judgments with
respect to future economic, competitive and market
conditions, future business decisions and regulatory
developments, all of which are difficult or impossible
to predict accurately and many of which are beyond
Milestone's control. Some of the important factors that
could cause actual results to differ materially from
those indicated by the forward-looking statements are
general economic conditions, failure to achieve expected
revenue growth, changes in our operating expenses,
adverse patent rulings, FDA or legal developments,
competitive pressures, changes in customer and market
requirements and standards, and the risk factors
detailed from time to time in Milestone's periodic
filings with the Securities and Exchange Commission,
including without limitation, Milestone's Annual Report
for the year ended December 31, 2019. The
forward-looking statements in this press release are
based upon management's reasonable belief as of the date
hereof. Milestone undertakes no obligation to revise or
update publicly any forward-looking statements for any
reaso